Progress towards gene therapy for cancer

Citation
C. Marchisone et al., Progress towards gene therapy for cancer, J EXP CL C, 19(3), 2000, pp. 261-270
Citations number
75
Categorie Soggetti
Oncology
Journal title
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
ISSN journal
03929078 → ACNP
Volume
19
Issue
3
Year of publication
2000
Pages
261 - 270
Database
ISI
SICI code
0392-9078(200009)19:3<261:PTGTFC>2.0.ZU;2-O
Abstract
This review highlights the current strategies being employed rewards gene t herapy of cancer. Conceptually, the most simple diseases to treat with gene therapy would be menogenic inherited diseases, such as hemophilia. However , the vast majority of current gene therapy trials are for treatment of can cer patients, due to the recognition of gene alterations in cancer and the critical need for improvement of cancer therapy. Gene-based therapies for c ancer in clinical trials include strategies that involve immune-therapy, in duction of drug sensitivity in tumor cells or resistance to chemotherapy of critical host tissues, and compensation for oncosuppressor loss or ablatio n of oncogenes. Two broad approaches have been used to deliver DNA to cells , a series of viral vectors and the use of plasmid DNA vectors, which have different advantages with regard to efficiency of gene transfer, ease of pr oduction and safety. Examined objectively, many of the first studies in cancer gene therapy clin ical trials have provided information of critical importance for the design of more efficient second-generation protocols. Gene therapy represents one of the most important developments in oncology, however, before this call be realized as standard treatment the technical problems of gene delivery a nd safety must be overcome. Here we focus on methods and strategies used to achieve cancer gene therapy and the current clinical trials.